论文部分内容阅读
为探讨纤溶系统活性与血瘀证的关系，对６２例血瘀证患者和６０名健康者进行了血浆组织型纤溶酶原激活物（ｔＰＡ）及其抑制物（ＰＡＩ）的活性测定，结果表明：血瘀证患者ｔＰＡ活性为（０．２７±０．０９）Ｕ／ｍｌ，显著低于对照组的（０．４７±０．１０）Ｕ／ｍｌ（Ｐ＜０．０１），而ＰＡＩ的活性为（０．７１±０．１６）Ｕ／ｍｌ，显著高于对照组的（０．５７±０．１４）Ｕ／ｍｌ（Ｐ＜０．０１），且二者均存在性别间的差异（Ｐ＜０．０１）；ｔＰＡ的阳性率为７９０％，ＰＡＩ的阳性率为４８４％，从而提示，血瘀证的发生与体内纤溶系统失衡有关，ｔＰＡ、ＰＡＩ的检测，对血瘀证的诊断、药物疗效观察均具有一定的临床实用价值。
In order to investigate the relationship between fibrinolytic system activity and blood stasis syndrome, 62 patients with blood stasis syndrome and 60 healthy subjects were studied for their activity of t-PA and its inhibitor (PAI) The results showed that the activity of t-PA in patients with blood stasis was (0.27 ± 0.09) U / ml, which was significantly lower than that in the control group (0.47 ± 0.10) U / ml (P <0. 01), while the activity of PAI was (0.71 ± 0.16) U / ml, which was significantly higher than that of the control group (0.57 ± 0.14) U / ml (P <0.01) (P <0.01). The positive rate of tPA was 790% and the positive rate of PAI was 484%, which suggested that the occurrence of blood stasis syndrome was imbalanced with the fibrinolytic system in vivo Related, t PA, PAI test, the diagnosis of blood stasis, the efficacy of drugs have a certain clinical value.